2. Immunology/Inflammation
  3. CD74
  4. Milatuzumab

Milatuzumab  (Synonyms: hLL1; MEDI-115)

Cat. No.: HY-P99731 Purity: 99.39%
COA

Molarity Calculator

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

For research use only. We do not sell to patients.

Milatuzumab Chemical Structure

Milatuzumab Chemical Structure

CAS No. : 899796-83-9

Size Price Stock Quantity
1 mg USD 350 In-stock
5 mg USD 910 In-stock
10 mg USD 1450 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Milatuzumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Milatuzumab

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].

IC50 & Target

CD74[1]
In Vitro

Milatuzumaba (5 μg/mL; 8-48 h) enhances cell death in MCL cell lines and primary patient tumor cells[1].
Milatuzumaba (5 μg/mL; 0.5-2 h) mediates the cytotoxicity partially depending on generation of ROS and loss of mitochondrial transmembrane potential in Jeko, Mino, and SP-53 cells[1].
Milatuzumaba (5 μg/mL; 4 h) inhibits NF-κB pathway and induces cell apoptosis with independent of caspase cleavage, Bcl-2 family member dysregulation, or induction of autophagy[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Milatuzumab Related Antibodies

Western Blot Analysis[1]

Cell Line: Jeko and Mino cells
Concentration: 5 μg/mL
Incubation Time: 4 hours
Result: Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.

Cell Viability Assay[1]

Cell Line: MCL cell lines and primarypatient tumor cells
Concentration: 5 μg/mL
Incubation Time: 8, 24, and 48 hours
Result: Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells.

Immunofluorescence[1]

Cell Line: Jeko, Mino, and SP-53 cells
Concentration: 5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h
Incubation Time: 0.5, 1, 1.5, and 2 hours
Result: Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.
In Vivo

Milatuzumaba (15 mg/kg/day; i.p.; once every 3 days) significantly increases the survival rate of female SCID mice bearing Jeko cells. And Milatuzumaba has a synergistic effect with Rituximab (HY-P9913) in mouse model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Jeko mouse model[1]
Dosage: 15 mg/kg/day; with or without 15 mg/kg Rituximab
Administration: Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
Result: Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Milatuzumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.39%

COA (231 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Milatuzumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Milatuzumab899796-83-9hLL1 MEDI-115hLL 1hLL-1MEDI115MEDI 115MEDI-115CD74HLA-DR-gammaInvariant polypeptide of major histocompatibility complex, class II antigen-associatedInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Milatuzumab
Cat. No.:
HY-P99731
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.